IBD Innovate Conference

Thetis Pharmaceuticals will be presenting a scientific poster on the planned continued development of TP-317 for Inflammatory Bowel Disease at the inaugural “IBD Innovate 2018” conference.

The day-long conference, hosted by the Crohn’s & Colitis Foundation and sponsored, in part, by Celgene Corporation, will be held on November 13, 2018, at the New York Academy of Medicine located in New York, NY. Additional conference details can be found on the Crohn’s & Colitis Foundation website, or by clicking here.